Levodopa-related wearing-off in Parkinson's disease: identification and management
- PMID: 19228103
- DOI: 10.1185/03007990902779319
Levodopa-related wearing-off in Parkinson's disease: identification and management
Abstract
Background: Levodopa is currently the most effective treatment for Parkinson's disease (PD); however, long-term levodopa therapy often results in motor complications, such as motor fluctuations and dyskinesia. The initial complication is commonly wearing-off, which is the re-emergence of motor and non-motor symptoms before the next scheduled levodopa dose.
Objective: The purpose of this article was to review published literature that discusses wearing-off, focusing on the role of the healthcare professional, including the primary care physician, in the effective management of wearing-off.
Methods: An electronic literature search was conducted using MEDLINE and EMBASE to find articles discussing wearing-off and its management using the following keywords: 'Parkinson's disease'; 'wearing-off'; 'levodopa'; 'primary care'.
Findings and conclusions: Current evidence indicates that a consistent delivery of levodopa should improve long-term symptomatic efficacy and may prevent or delay motor complications. A number of therapeutic options are available to optimize therapeutic outcome, including modification of the levodopa dose or dosing schedule,switching to another levodopa formulation and the use of adjunct therapies, such as catechol-O-methyl transferase inhibitors, dopamine agonists and monoamine oxidase-B inhibitors. The management of wearing-off is dependent upon the early identification of symptoms and the initiation of effective treatment. Key issues are the need to educate patients and to facilitate good communication with both primary and secondary healthcare professionals. In most cases, patients with PD initially present to primary healthcare professionals who may refer the patient to a neurologist once disease management becomes more complex. However, in many cases, especially in rural areas where neurologists may not be widely available, the primary healthcare professionals may manage the patient throughout the disease course. Limitations of this review include the restricted search criteria and selected search period.
Similar articles
-
Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.Ann Pharmacother. 2007 Nov;41(11):1842-9. doi: 10.1345/aph.1K348. Epub 2007 Sep 18. Ann Pharmacother. 2007. PMID: 17878397 Review.
-
Medical management of levodopa-associated motor complications in patients with Parkinson's disease.CNS Drugs. 2007;21(8):677-92. doi: 10.2165/00023210-200721080-00005. CNS Drugs. 2007. PMID: 17630819 Review.
-
Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.J Am Med Dir Assoc. 2006 Sep;7(7 Suppl 2):12-7. J Am Med Dir Assoc. 2006. PMID: 17948614 Review.
-
Parkinson's disease--levodopa complications.Can J Neurol Sci. 1999 Aug;26 Suppl 2:S13-20. doi: 10.1017/s0317167100000044. Can J Neurol Sci. 1999. PMID: 10451755 Review.
-
Other pharmacological treatments for motor complications and dyskinesias.Mov Disord. 2005;20 Suppl 11:S38-44. doi: 10.1002/mds.20462. Mov Disord. 2005. PMID: 15822104 Review.
Cited by
-
Structural Changes Observed in the Piriform Cortex in a Rat Model of Pre-motor Parkinson's Disease.Front Cell Neurosci. 2018 Dec 10;12:479. doi: 10.3389/fncel.2018.00479. eCollection 2018. Front Cell Neurosci. 2018. PMID: 30618629 Free PMC article.
-
Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease: a pilot study.Neurol Sci. 2018 Jan;39(1):141-143. doi: 10.1007/s10072-017-3123-2. Epub 2017 Sep 27. Neurol Sci. 2018. PMID: 28956175
-
Pain-Related Abnormal Neuronal Synchronization of the Nucleus Accumbens in Parkinson's Disease.Brain Sci. 2022 Jan 7;12(1):84. doi: 10.3390/brainsci12010084. Brain Sci. 2022. PMID: 35053828 Free PMC article.
-
Parkinson's Disease: From Pathogenesis to Pharmacogenomics.Int J Mol Sci. 2017 Mar 4;18(3):551. doi: 10.3390/ijms18030551. Int J Mol Sci. 2017. PMID: 28273839 Free PMC article. Review.
-
Role of Molecular, Crystal, and Surface Chemistry in Directing the Crystallization of Entacapone Polymorphs on the Au(111) Template Surface.Cryst Growth Des. 2023 May 1;23(6):4522-4537. doi: 10.1021/acs.cgd.3c00294. eCollection 2023 Jun 7. Cryst Growth Des. 2023. PMID: 37304395 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical